Sciele Pharma and Addrenex Pharmaceuticals Inc. announced that they have initiated patient enrollment for U.S. Phase III clinical trials of Clonicel to treat attention deficit and hyperactivity disorder in children.

In July, Atlanta-based Sciele signed an exclusive licensing agreement with Addrenex to market a sustained-release formulation of clonidine hydrochloride for the treatment of ADHD and hypertension.

Sciele Pharma, Inc. is a pharmaceutical company specializing in sales, marketing and development of branded prescription products focused on Cardiovascular/Diabetes, Women's Health and Pediatrics. The Company's Cardiovascular/Diabetes products treat patients with high cholesterol, hypertension, high triglycerides, unstable angina and Type 2 diabetes; its Women's Health products are designed to improve the health and well-being of women and mothers and their babies; and its Pediatrics products treat allergies, asthma, coughs and colds, and attention deficit/hyperactivity disorder (ADHD).

Addrenex Pharmaceuticals is a focused, specialty pharmaceutical company that develops and commercializes drugs to regulate the adrenergic and noradrenergic systems and help patients with adrenergia-related medical conditions. The company develops drugs, diagnostic tools and intervention methods designed to improve the likelihood of a successful outcome of treatment for adrenergia-related conditions.